HS627 (pertuzumab biosimilar)
/ Zhejiang Hisun Pharmaceutical, BioRay Biopharmaceutical, Betta Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 4
Of
4
Go to page
1
November 22, 2025
Treatment of Breast Cancer With Trastuzumab + HS627/ Pertuzumab + Docetaxel
(clinicaltrials.gov)
- P3 | N=408 | Active, not recruiting | Sponsor: BioRay Pharmaceutical Co., Ltd. | Recruiting ➔ Active, not recruiting | Trial completion date: Nov 2021 ➔ Dec 2025
Enrollment closed • Trial completion date • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • ER • HER-2 • PGR
July 12, 2023
Comparison of Pharmacokinetics and Safety of HS627(2 Specifications) Versus PERJETA With a Single Injection
(clinicaltrials.gov)
- P1 | N=180 | Completed | Sponsor: Zhe Jiang Hisun Bioray Bio-pharmaceu tical Co.Ltd | Not yet recruiting ➔ Completed
Trial completion
April 12, 2022
Comparison of Pharmacokinetics and Safety of HS627(2 Specifications) Versus PERJETA With a Single Injection
(clinicaltrials.gov)
- P1 | N=180 | Not yet recruiting | Sponsor: Zhe Jiang Hisun Bioray Bio-pharmaceu tical Co.Ltd
New P1 trial
August 17, 2020
Treatment of Breast Cancer With Trastuzumab + HS627/ Pertuzumab + Docetaxel
(clinicaltrials.gov)
- P3; N=408; Recruiting; Sponsor: Zhe Jiang Hisun Bioray Bio-pharmaceu tical Co.Ltd
Clinical • Combination therapy • New P3 trial • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Oncology • Solid Tumor • ER • HER-2 • PGR
1 to 4
Of
4
Go to page
1